Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells

被引:12
作者
Funato, T
Kozawa, K
Kaku, M
Sasaki, T
机构
[1] Tohoku Univ, Sch Med, Dept Clin Med, Div Mol Diagnost, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Sch Med, Dept Clin Med, Div Rheumatol & Hematol, Sendai, Miyagi 9808574, Japan
关键词
antisense oligonucleotides; apoptosis; cisplatin; c-myc; colon cancer; drug resistance;
D O I
10.1097/00001813-200111000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human colon cancer SW480 cells express the c-myc gene. On the other hand, SW480DDP cell lines resistant to cisplatin exhibited decreased c-myc gene expression, but their cell growth rates remained similar to those of their parental cells. Antisense oligonucleotides to c-myc inhibited c-myc expression and induced increased resistance to cisplatin in SW480 cells. In contrast, SW480DDP cells showed increased c-myc expression and reversed sensitivity to cisplatin when these cells were transfected with c-myc cDNA from the pLNCX plasmid. Moreover, SW480DDP cells transfected with c-myc cDNA induced apoptosis when exposed to cisplatin, but not SW480 cells transfected with an antisense sequence for c-myc. Transfection either with a c-myc antisense sequence or c-myc cDNA to these cells did not change their growth rates. Thus enforced expression of c-myc in SW480 and SW620 lines sensitizes cells to cisplatin-induced apoptosis, whereas the down-regulation of c-myc in SW480DDP and SW620DDP increases cisplatin resistance when using antisense strategy. [(C) 2001 Lippincott Williams & Wilkins.].
引用
收藏
页码:829 / 834
页数:6
相关论文
共 28 条
[1]  
Akiyama S, 1999, ANTI-CANCER DRUG DES, V14, P143
[2]  
CERUTTI J, 1996, CLIN CANCER RES, V2, P19
[3]  
Citro G, 1998, CANCER RES, V58, P283
[4]  
Fink D, 1996, CANCER RES, V56, P4881
[5]   Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA [J].
Fujimoto, K ;
Takahashi, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 241 (03) :775-781
[6]  
FUNATO T, 1992, ADV ENZYME REGUL, V32, P195
[7]   IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[8]   Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin [J].
Go, RS ;
Adjei, AA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :409-422
[9]  
Hashiramoto A, 1999, ARTHRITIS RHEUM, V42, P954, DOI 10.1002/1529-0131(199905)42:5<954::AID-ANR14>3.0.CO
[10]  
2-J